Tag: AMyris

Navy and Amyris team on developing jet biofuel

Navy and Amyris team on developing jet biofuel

October 6, 2020 |

In California, biosynthetic research is being done in China Lake, California, by Naval Air Warfare Center Weapons Division and Amyris, Inc. Funded by the Defense Advanced Research Projects Agency’s Living Foundries: 1000 Molecules Program, NAWCWD and Amyris’ project starts with specially developed yeast cells and ends with a high-density missile fuel. Through the Living Foundries […]

Read More

Amyris trialing bio-based vaccine adjuvants to replace demand for deep-sea shark livers

Amyris trialing bio-based vaccine adjuvants to replace demand for deep-sea shark livers

October 1, 2020 |

In California, Amyris, Inc. is currently delivering samples to pharmaceutical companies of a sustainable and scalable alternative to shark-based vaccine adjuvants currently used in a number of vaccines, including those directed at influenza and COVID-19. Amyris expects commercialization and production of its alternative squalene for adjuvants in the fourth quarter. Adjuvants are added to vaccines […]

Read More

Amyris responds to LAVVAN’s lawsuit filing, clarifies 3 points

Amyris responds to LAVVAN’s lawsuit filing, clarifies 3 points

September 13, 2020 |

In California, Amyris, Inc. responds to LAVVAN, Inc.’s press release related to its commencement of a lawsuit against Amyris for patent infringement and trade secret misappropriation and submitted this statement to clarify several points. Amyris and LAVVAN entered into a Research, Collaboration and License Agreement in March 2019 valued at $300 million in milestone payments […]

Read More

Amyris scales up commercial production of fermented CBG

Amyris scales up commercial production of fermented CBG

September 1, 2020 |

In California, Amyris has successfully scaled up the commercial production of Cannabigerol (CBG) leveraging its industrial fermentation process capability. Amyris expects to deliver about one ton of high purity CBG through fermentation as an alternative to the traditional production method of extraction from the Cannabis sativa L. plant. First commercial revenue from the sale of […]

Read More

Ch-Ch-Ch-Changes…Amyris turns to face the strange with sugarcane-derived squalene vaccine adjuvant

Ch-Ch-Ch-Changes…Amyris turns to face the strange with sugarcane-derived squalene vaccine adjuvant

August 9, 2020 |

COVID-19 has changed the way we do things…like drink more alcohol, wash our hands more, wear a mask, limit our gatherings and trips, but positive things have come about too. More time to connect with friends and family via online tools, a new respect for healthcare, agriculture and other essential workers, breathing cleaner air, and […]

Read More

Amyris JV launches plant-derived silica made from sugarcane ashes

Amyris JV launches plant-derived silica made from sugarcane ashes

July 19, 2020 |

In California, Aprinnova, Inc., an Amyris, Inc. joint venture, the leading supplier of high performance, clean beauty ingredients is commercializing a plant-derived silica made from sugarcane ashes. Silica is used widely in personal care and cosmetics. It is traditionally sourced from non-renewable sand dredging, which requires significant energy consumption and emits large amounts of C02. […]

Read More

Amyris’s Biossance launches $10K award for science, innovation, social impact

Amyris’s Biossance launches $10K award for science, innovation, social impact

July 5, 2020 |

In California, Amyris’s Biossance brand launched The Clean Academy by Biossance Impact Award to discover and foster the growth of future sustainability and environmental leaders, offering $10,000 for each winner in two categories – Science and Innovation and Social Impact. Entries will be judged by a multi-disciplinary panel of experts. The leading applicant in each […]

Read More

Amyris raises $200M from private placement

Amyris raises $200M from private placement

June 7, 2020 |

In California, Amyris, Inc., executed a binding funding agreement with leading institutional investors to raise $200 million at $3.00 per common share through a private investment in public equity in the Company and expects to use the proceeds from the offering for general corporate purposes and to repay certain outstanding indebtedness by approximately $61 million […]

Read More

Amyris launches safe alternative to talc-based baby powder on heels of J&J announcement

Amyris launches safe alternative to talc-based baby powder on heels of J&J announcement

May 24, 2020 |

In California, Amyris launched “Baby Cream to Powder”, a talc-free alternative to baby powder made with 100% sugarcane-derived squalane, just as Johnson & Johnson announced they will stop selling talcum-based baby powder in the U.S. and Canada. The talc-free baby powder was launched under its Pipette baby brand. As with all Pipette products, 100% sugarcane-derived […]

Read More

Amyris gets GRAS validation for new health and nutrition ingredient

Amyris gets GRAS validation for new health and nutrition ingredient

May 17, 2020 |

In California, Amyris, Inc. reports that its first health and nutrition ingredient received a validation by a unanimous Panel of Medical Experts as Generally Recognized As Safe (“GRAS”). Following this successful validation, Amyris will submit an application for FDA GRAS approval of this ingredient (currently not being named due to partner’s requirements), which has the […]

Read More